SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
  
 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
  
 Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Allan Jonathan
(Last) (First) (Middle)
C/O STOKE THERAPEUTICS, INC.
45 WIGGINS AVENUE
(Street)
BEDFORD MA 01730
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Stoke Therapeutics, Inc. [ STOK ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
General Counsel & Corp Sec
3. Date of Earliest Transaction (Month/Day/Year)
12/01/2023
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Employee Stock Option (Right to Buy) $59.84 12/01/2023 D 65,000 (1) 02/15/2031 Common Stock 65,000 (2) 0 D
Employee Stock Option (Right to Buy) $20.34 12/01/2023 D 121,100 (3) 03/14/2032 Common Stock 121,100 (4) 0 D
Restricted Stock Unit (RSU) (5) 12/01/2023 A 46,284 (6) 12/01/2025 Common Stock 46,284 $0.00 46,284 D
Explanation of Responses:
1. The canceled option vested as to 1/4th of the total award on February 16, 2022, and provided for 1/48th of the total award to vest monthly thereafter, subject to the reporting person's continued service to the Issuer through each vesting date.
2. On December 1, 2023, the Issuer cancelled, pursuant to the Issuer's option exchange program, options to purchase 65,000 shares of Common Stock of the Issuer and in exchange issued to the reporting person 8,441 restricted stock units.
3. The canceled option vested as to 1/48th of the total award on April 15, 2022 and provided for 1/48th of the total award to vest monthly thereafter, subject to the reporting person's continued service to the Issuer through each vesting date.
4. On December 1, 2023, the Issuer cancelled, pursuant to the Issuer's option exchange program, options to purchase 121,100 shares of Common Stock of the Issuer and in exchange issued to the reporting person 37,843 restricted stock units.
5. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock.
6. 33,927 restricted stock units will vest on December 1, 2024 and 12,357 will vest on December 1, 2025, subject to the reporting person's continued service to the Issuer on each such date.
Remarks:
/s/ Stephen Tulipano, Attorney-in-Fact 12/05/2023
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Stoke Therapeutics (NASDAQ:STOK)
Gráfica de Acción Histórica
De Sep 2024 a Oct 2024 Haga Click aquí para más Gráficas Stoke Therapeutics.
Stoke Therapeutics (NASDAQ:STOK)
Gráfica de Acción Histórica
De Oct 2023 a Oct 2024 Haga Click aquí para más Gráficas Stoke Therapeutics.